ATAI Life Sciences B.V.* ATAI 深 沪
已收盘 10-31 16:00:00 美东时间
5.84
+0.060
+1.04%
华盛通- 最 高5.915
- 今 开5.76
- 成交量 449.32万股
- 最 低 5.66
- 昨 收 5.78
- 总市值 13.67亿
- 52周最高 6.75
- 市盈率 静 --
- 换手率 1.92%
- 52周最低 1.15
- 委 比 -98.95%
- 总股本 2.34亿
- 历史最高 22.91
- 量 比 0.84
- 振 幅 4.41%
- 历史最低 1.025
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
ATAI Life Sciences Closes $149.5 Million Public Offering
ATAI Life Sciences ( ($ATAI) ) has provided an announcement. On October 20, 202...
10-21 21:58
ATAI Life Sciences’ BPL-003 Receives FDA Breakthrough Designation
ATAI Life Sciences ( ($ATAI) ) has provided an announcement. On October 16, 202...
10-17 05:19
atai Life Sciences Announces Pricing of Public Offering of Common Shares
Biopharmaceutical company atai Life Sciences announced a registered underwritten offering of 23,725,000 common shares at $5.48 per share, with an option for underwriters to purchase up to an additional 3,558,750 shares. The offering, expected to close on October 20, 2025, will provide gross proceeds of approximately $130 million. Proceeds will be used to advance clinical development of psychedelic-based therapies for mental health disorders and g...
10-17 02:31
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
The U.S. FDA has granted Breakthrough Therapy designation to BPL-003 nasal spray for adult patients with treatment-resistant depression (TRD). The designation, recognizing its potential for substantial improvement over existing therapies, follows positive Phase 2b topline data showing rapid and durable antidepressant effects with a single dose. BPL-003, developed by Beckley Psytech and supported by atai Life Sciences, aims to address the urgent u...
10-16 20:10
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Needham Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $12
Needham analyst Ami Fadia initiates coverage on ATAI Life Sciences (NASDAQ:ATAI) with a Buy rating and announces Price Target of $12.
10-13 18:08
ATAI Life Sciences to Acquire Beckley Psytech
ATAI Life Sciences ( ($ATAI) ) just unveiled an announcement. ATAI Life Science...
10-11 04:49
Atai Life Sciences files to sell 45.32M common shares by selling shareholders
Atai Life Sciences (NASDAQ:ATAI) filed to sell 45.32 million common stock. The company will not receive any proceeds from the sale of common stocks by the selling shareholder. Filing More on ATAI Life...
09-30 05:40
